Immune-Cell-Based Therapy for COVID-19: Current Status

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy t...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2023-10, Vol.15 (11), p.2148
Main Authors: Wang, Yiyuan, Liang, Qinghe, Chen, Fengsheng, Zheng, Jiehuang, Chen, Yan, Chen, Ziye, Li, Ruopeng, Li, Xiaojuan
Format: Article
Language:English
Subjects:
Antigens
Bone marrow
Cell therapy
Cell- and Tissue-Based Therapy
Cells
Clinical trials
Coronaviruses
COVID-19
COVID-19 - therapy
COVID-19 Drug Treatment
Cytokines
Cytotoxicity
Fatalities
Health aspects
Humans
Immune response
Immunity, Innate
Immunotherapy
Infections
Infectious diseases
Inflammation
Lymphocytes
Medical research
Medicine, Experimental
Pathogenesis
Proteins
Respiratory distress syndrome
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Thymus gland
Umbilical cord
Viral infections
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.
ISSN:1999-4915
1999-4915
DOI:10.3390/v15112148